Cencora Completes OneOncology Acquisition, Lifts Guidance

Cencora ( (COR) ) just unveiled an announcement.

For its fiscal 2026 first quarter ended December 31, 2025, Cencora reported revenue of $85.9 billion, up 5.5% year over year, with GAAP diluted EPS rising to $2.87 from $2.50 and adjusted diluted EPS increasing 9.4% to $4.08. The company delivered double‑digit growth in adjusted operating income to $1.1 billion, supported by higher gross profit in both reporting segments and margin expansion driven partly by the January 2025 acquisition of Retina Consultants of America, though operating expenses also climbed on acquisition-related costs and an impairment in its U.S. Consulting Services business. On February 2, 2026, Cencora completed the $4.6 billion cash acquisition of the OneOncology stake it did not already own, funded with new debt, and will consolidate OneOncology’s results within U.S. Healthcare Solutions; management simultaneously raised its fiscal 2026 adjusted operating income growth outlook to 11.5%–13.5%, signaling confidence that the enlarged specialty MSO platform and stronger oncology positioning will enhance long-term earnings power despite higher interest expense and ongoing portfolio reshaping.

The most recent analyst rating on (COR) stock is a Buy with a $400.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Spark’s Take on COR Stock

According to Spark, TipRanks’ AI Analyst, COR is a Neutral.

The score is driven mainly by solid financial performance (notably strong cash generation) and a positive earnings outlook with raised guidance. Offsetting these strengths are high leverage and a rich valuation (high P/E, low yield), while technicals are supportive but not decisively strong due to near-overbought signals.

To see Spark’s full report on COR stock, click here.

More about Cencora

Cencora, Inc., listed on the NYSE under ticker COR, operates in the healthcare distribution and solutions industry, with operations organized into U.S. Healthcare Solutions and International Healthcare Solutions segments. The company focuses on pharmaceutical-centric services and specialty management service organizations (MSOs), including recent expansion in oncology and retinal care through acquisitions such as Retina Consultants of America and, most recently, OneOncology, to deepen its specialty footprint and partnerships with physician-led practices.

Average Trading Volume: 1,398,471

Technical Sentiment Signal: Buy

Current Market Cap: $70.72B

For detailed information about COR stock, go to TipRanks’ Stock Analysis page.